Positron emission tomography combined with serum biomarkers detects fibrotic MASH

期刊论文
出版模式：

开放获取
发表日期：

2024年9月20日

查看全文

Sean Romeo,
Connie Chan,
Karen Matsukuma,
Michael T. Corwin,
Victoria Lyo,
Shuai Chen,
Guobao Wang,
Souvik Sarkar

摘要

Metabolic dysfunction-associated steatohepatitis (MASH) is a rising global disease signaling the urgent need for non-invasive tests (NITs). Recent work demonstrated that dynamic ¹⁸F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) imaging can identify MASH by measuring liver glucose transport rate, K₁, and liver CT attenuation. By combining dynamic PET/CT with the serum-based fibrosis-4 (FIB-4) test, we were able to better distinguish clinical MASH from fibrotic subtypes, enabling determination of the core tenets of MASH: steatosis, inflammation, and fibrosis. Future studies using FDG-PET technology can further enable concomitant prediction of MASH severity and extrahepatic comorbidities such as cardiovascular disease.